Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action

J Clin Psychiatry. 2001 Dec;62(12):923-4. doi: 10.4088/jcp.v62n1201.
No abstract available

MeSH terms

  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Aripiprazole
  • Basal Ganglia Diseases / chemically induced
  • Basal Ganglia Diseases / prevention & control
  • Humans
  • Piperazines / adverse effects
  • Piperazines / therapeutic use*
  • Quinolones / adverse effects
  • Quinolones / therapeutic use*
  • Receptors, Dopamine D2 / drug effects*
  • Receptors, Dopamine D2 / physiology
  • Schizophrenia / drug therapy*
  • Schizophrenia / physiopathology
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Piperazines
  • Quinolones
  • Receptors, Dopamine D2
  • Aripiprazole